03 September 2010
Keywords: Ipsen, Debipharm, Decapeptyl, prostate cancer, Recordati, silodosin, Prostatic hyperplasia
Article | 4 February 2010
French specialty drugmaker Ipsen and Swiss biopharmaceutical group Debiopharm have announced the launch by Ipsen in France of Decapeptyl (triptorelin embonate1) LP 22.5mg six-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer. Other launches are planned shortly, notably in Germany and Portugal.
The marketing authorization (MA) to this formulation of Decapeptyl was granted on November 10, 2009, by the French regulatory authority (Agence Française de Securite Sanitaire des Produits de Sante, AFSSAPS) for the treatment of locally advanced and metastatic hormone-dependent prostate cancer. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.